Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'
1. Axsome settles patent litigation with Teva over Auvelity. 2. Generic sales for Auvelity start in 2038 or 2039. 3. Auvelity shows promising sales growth at $92.6 million for Q4 2024. 4. Analysts rate Axsome highly based on litigation outcome and product growth. 5. Axsome perceived as potential acquisition target by larger pharmaceutical firms.